Clozapine modulation of zebrafish swimming behavior and gene expression as a case study to investigate effects of atypical drugs on aquatic organisms

Mental illnesses affect more than 150 million people in Europe and lead to an increasing consumption of neuroactive drugs during the last twenty years. The antipsychotic compound, clozapine, is one of the most used psychotropic drugs worldwide, with potentially negative consequences for the aquatic environment. Hence, the objectives of the study presented here were the quantification of clozapine induced changes in swimming behavior of exposed Danio rerio embryos and the elucidation of the molecular effects on the serotonergic and dopaminergic systems. Yolk-sac larvae were exposed to different concentrations (0.2 mg/L, 0.4 mg/L, 0.8 mg/L, 1.6 mg/L, 3.2 mg/L and 6.4 mg/L) of clozapine for 116 h post-fertilization, and changes in the swimming behavior of the larvae were assessed. Further, quantitative real-time PCR was performed to analyze the expression of selected genes. The qualitative evaluation of changes in the swimming behavior of D. rerio larvae revealed a significant decrease of the average swimming distance and velocity in the light-dark transition test, with more than a 36% reduction at the highest exposure concentration of 6.4 mg/L. Furthermore, the total larval body length was reduced at the highest concentration. An in-depth analysis based on expression of selected target genes of the serotonin (slc6a4a) and dopamine (drd2a) system showed an upregulation at a concentration of 1.6 mg/L and above. In addition, a lower increase in expression was detected for biomarkers of general stress (adra1a and cyp1a2). Our data show that exposure to clozapine during development inhibits swimming activity of zebrafish larvae, which could, in part, be due to disruption of the serotonin- and dopamine system.

Status of cathelicidin IL-37, cytokine TNF, and vitamin D in patients with pulmonary tuberculosis

Development of Mycobacterium tuberculosis (Mtb) infection depends on the ability of the host to elicit the protective immune response to the pathogen. Cathelicidin plays a role in antibacterial innate immunity mechanisms. This peptide contributes to the barrier function of respiratory epithelium and takes part in controlling pulmonary bacterial infections. LL-37 (leucine-leucine-37) is involved in host defense and innate immune response to mycobacterial infections, as well. This study aims to evaluate the serum concentrations of LL-37 in individuals with active pulmonary tuberculosis (TB) and to determine whether any correlations between peptide LL-37, tumor necrosis factor (TNF) and vitamin D serum levels exist. A total of 46 adults with pulmonary TB were recruited for the study. Sixty-one controls were randomly selected as control group. Serum concentrations of cathelicidin LL-37, vitamin D (25(OH)D), as well as TNF, were measured using an enzyme-linked immunosorbent assay (ELISA) kit. The mean (± SEM) level of LL-37 was significantly higher in the TB group (7.45±1.58) compared with healthy controls (1.41±0.22) (p less than 0.001). Mean serum concentration of TNF was significantly higher in the TB group (8.51±1.92) compared with healthy controls (2.69±0.19) (p less than 0.001). There was no significant difference in mean serum levels of vitamin D between healthy (26.10±1.74) and TB subjects (24.18±1.95). No correlations between LL-37, TNF, and vitamin D levels in patients with TB were observed. Our results indicated that serum levels of peptide LL-37 during TB is raised significantly, and this observation is compatible with the general view of the important role of this cathelicidin in defense mechanisms against Mtb infection.

Serum level of cathelicidin LL-37 in patients with active tuberculosis and other infectious diseases

A growing body of evidence indicates the role of cathelicidin LL-37, a member of the antimicrobial peptide family, in host innate defense mechanisms. The important role of this peptide in infectious diseases is also suggested, however, to date, data relating to LL-37 expression in the course of bacterial infections are far from complete. Therefore, the aim of the present study was to determine LL-37 serum levels in adult patients with pulmonary tuberculosis (TB). For comparison, circulating LL-37 levels in patients with pneumonia induced by Gram-positive or Gram-negative bacteria species and in healthy subjects were evaluated. Fifty patients with pulmonary TB, 31 patients with pneumonia caused by gram-positive bacteria, 68 individuals with pneumonia caused by Gram-negative bacteria, and 61 randomly selected healthy subjects were enrolled in the study. Serum LL-37 concentration was measured using an enzyme-linked immunosorbent assay (ELISA). We established that the mean level of LL-37 was statistically significantly higher in TB patients than that in patients with Gram-positive bacteria-induced pneumonia (p < 0.001), in patients with Gram-negative bacteria-induced pneumonia (p < 0.001), and in healthy controls (p < 0.001). In patients with TB, no statistically significant correlations between serum LL-37 and CRP concentrations (r = -0.2042; p = 0.189) and between serum LL-37 concentration and WBC count (r = -0.1277; p = 0.414) were observed. Our observations clearly documented that cathelicidin LL-37 plays a role in defense mechanisms against infectious agents, and is particularly important when the infection is caused by an intracellular pathogen.